Maternal and Neonatal Circulating Markers of Metabolic and Cardiovascular Risk in the Metformin in Gestational Diabetes (MiG) Trial
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study was designed to compare glucose, lipids, and C-reactive protein (CRP) in women with gestational diabetes mellitus treated with metformin or insulin and in cord plasma of their offspring and to examine how these markers relate to infant size at birth. RESEARCH DESIGN AND METHODS: Women with gestational diabetes mellitus were randomly assigned to metformin or insulin in the Metformin in Gestational Diabetes trial. Fasting maternal plasma glucose, lipids, and CRP were measured at randomization, 36 weeks’ gestation, and 6–8 weeks postpartum as well as in cord plasma. Women with available cord blood samples (metformin n = 236, insulin n = 242) were included. RESULTS: Maternal plasma triglycerides increased more from randomization to 36 weeks’ gestation in women treated with metformin (21.93%) versus insulin (9.69%, P < 0.001). Maternal and cord plasma lipids, CRP, and neonatal anthropometry did not differ between treatments. In logistic regression analyses adjusted for confounders, the strongest associations with birth weight >90th centile were maternal triglycerides and measures of glucose control at 36 weeks. CONCLUSIONS: There were few differences in circulating maternal and neonatal markers of metabolic status and no differences in measures of anthropometry between the offspring of women treated with metformin and the offspring of women treated with insulin. There may be subtle effects of metformin on maternal lipid function, but the findings suggest that treating gestational diabetes mellitus with metformin does not adversely affect lipids or CRP in cord plasma or neonatal anthropometric measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
Bellamy, L., Casas, J.-P., Hingorani, A. D., & Williams, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60731-5 · Cited by 3,253 · cited 1×
“Women with a history of gestational diabetes mellitus are at risk for metabolic syndrome, type 2 diabetes (5), and cardiovascular disease in later life (6).”
BackgroundEffect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Self-citationKirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084 · cited 1×
“In addition to improving insulin sensitivity and hyperglycemia, metformin therapy in the setting of type 2 diabetes reduces triglycerides (9), total cholesterol, LDL cholesterol (10), and VLDL cholesterol; increases HDL cholesterol (9); and reduces markers of inflammation and thrombosis (11).”
BackgroundInsulin effects in muscle and adipose tissue
Dimitriadis, G., Mitrou, P., Lambadiari, V., Maratou, E., & Raptis, S. A. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70014-6 · Cited by 649 · cited 1×
“Previous studies in type 2 diabetes outside pregnancy have suggested that metformin improves lipid profiles, with a decline in triglycerides and LDL cholesterol and an elevation in HDL cholesterol (10), whereas insulin decreases lipolysis in adipose tissue, thereby reducing free fatty acids and hepatic synthesis of tr…”
BackgroundSchaefer-Graf, U. M., Graf, K., Kulbacka, I., Kjos, S. L., Dudenhausen, J., Vetter, K., & Herrera, E. (2008) · Diabetes Care · doi:10.2337/dc08-0039 · Cited by 439 · cited 4×
“Maternal triglycerides have been reported to be positively correlated with cord blood triglycerides in women with well-controlled gestational diabetes (20).”
BackgroundResultInfluentialMetformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)
Rowan, J. A., Rush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Hague, W. M. (2011) · Diabetes Care · doi:10.2337/dc11-0660 · Cited by 379
Self-citationGestational Diabetes: Implications for Cardiovascular Health
Sullivan, S. D., Umans, J. G., & Ratner, R. (2012) · Current Diabetes Reports · doi:10.1007/s11892-011-0238-3 · Cited by 143 · cited 1×
“Women with a history of gestational diabetes mellitus are at risk for metabolic syndrome, type 2 diabetes (5), and cardiovascular disease in later life (6).”
BackgroundTransfer of metformin across the dually perfused human placental lobule
Nanovskaya, T. N., Nekhayeva, I. A., Patrikeeva, S. L., Hankins, G. D. V., & Ahmed, M. S. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.05.047 · Cited by 98 · cited 1×
“In contrast to insulin, metformin crosses the placenta (14) and, therefore, could directly influence fetal metabolism.”
Background
Cited by
Insulin for the treatment of women with gestational diabetes
Brown, J., Grzeskowiak, L., Williamson, K., Downie, M. R., & Crowther, C. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012037.pub2 · Cited by 158
Feng, Y., & Yang, H. (2017) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2016.1228061 · Cited by 68
Metformin versus insulin for gestational diabetes mellitus: a meta-analysis
Zhao, L., Sheng, X., Zhou, S., Yang, T., Ma, L., Zhou, Y., & Cui, Y. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12672 · Cited by 63
Li, G., Zhao, S., Cui, S., Li, L., Xu, Y., & Li, Y. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-014-3566-0 · Cited by 54
Pharmacotherapy for gestational diabetes
Patti, A. M., Giglio, R. V., Pafili, K., Rizzo, M., & Papanas, N. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1509955 · Cited by 19
Metadata
- Authors
- Barrett, H. L., Gatford, K. L., Houda, C. M., De Blasio, M. J., McIntyre, H. D., Callaway, L. K., Dekker Nitert, M., Coat, S., Owens, J. A., Hague, W. M., & Rowan, J. A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-02-13
- Volume
- 36
- Issue
- 3
- Pages
- 529-536
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2128065457
- Cited by
- 51
- References
- 10
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maternal and Neonatal Circulating Markers of Metabolic and Cardiovascular Risk in the Metformin in Gestational Diabetes (MiG) Trial. https://app.cochat.ai/papers/10.2337/dc12-1097
- The paper
- Barrett, H. L., Gatford, K. L., Houda, C. M., De Blasio, M. J., McIntyre, H. D., Callaway, L. K., Dekker Nitert, M., Coat, S., Owens, J. A., Hague, W. M., & Rowan, J. A. (2013). Maternal and Neonatal Circulating Markers of Metabolic and Cardiovascular Risk in the Metformin in Gestational Diabetes (MiG) Trial. Diabetes Care. https://doi.org/10.2337/dc12-1097
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.